Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Symptom Cluster

erlotinib hydrochloride has been researched along with Symptom Cluster in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Diab, Y; Diamond, C; Duchatelet, S; Hill, I; Hovnanian, A; Kirkorian, AY; Lakdawala, N; Marathe, K; Richard, G; Siegel, DH; Tower, RL; Watanabe, F; Zhang, A1
Bodemer, C; Boucheix, C; Chaumon, S; Doz, F; Greco, C; Hadj-Rabia, S; Leclerc-Mercier, S; Molina, T1
Descourt, R; Misery, L; Roguedas, AM; Rouxel, AM1
Afifi, Y; Benomar, S; Bouhllab, J; Boutayeb, S; Errihanni, H; Hamada, S; Hassam, B1
Fang, Z; Li, B; Zang, YS1

Other Studies

5 other study(ies) available for erlotinib hydrochloride and Symptom Cluster

ArticleYear
Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome.
    JAMA dermatology, 2020, 02-01, Volume: 156, Issue:2

    Topics: Adolescent; Brazil; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunosuppressive Agents; Infant; Keratoderma, Palmoplantar; Male; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; Syndrome; TOR Serine-Threonine Kinases; Treatment Outcome

2020
Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations.
    JAMA dermatology, 2020, 02-01, Volume: 156, Issue:2

    Topics: Adolescent; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Keratoderma, Palmoplantar; Male; Mutation; Protein Kinase Inhibitors; Syndrome; TRPV Cation Channels

2020
[Hand-foot syndrome: A new side effect of erlotinib].
    Annales de dermatologie et de venereologie, 2008, Volume: 135, Issue:11

    Topics: Aged; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Erythema; Foot Dermatoses; Foot Diseases; Hand Dermatoses; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Syndrome

2008
Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
    Dermatology online journal, 2009, Nov-15, Volume: 15, Issue:11

    Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dermatitis, Seborrheic; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Syndrome

2009
Erlotinib plus parenteral nutrition: an opportunity to get through the hardest days of advanced non-small cell lung cancer with cancer anorexia-cachexia syndrome.
    The American journal of hospice & palliative care, 2013, Volume: 30, Issue:2

    Topics: Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Parenteral Nutrition; Quinazolines; Syndrome

2013